CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response

Oncotarget

Volumn 5, Issue 8, 2014, Pages 2330-2343

  Saucedo Cuevas, Laura P ^a   Ruppen, Isabel ^a   Ximénez Embún, Pilar ^a   Domingo, Samuel ^a   Gayarre, Javier ^a,c   Muñoz, Javier ^a   Silva, Jose M ^b   García, María J ^a,c   Benítez, Javier ^a,c  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

13q34 amplification; Basal like; Breast cancer; CUL4A; Immune system; Proteomics

Indexed keywords

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CUL4A GENE; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE C MYC; ONCOGENE H RAS; PHENOTYPE; PROTEIN TARGETING; PROTEOMICS; TUMOR IMMUNITY; UPREGULATION; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

CUL4A PROTEIN, HUMAN; CULLIN; TRANSCRIPTOME;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CULLIN PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84899526918     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1915     Document Type: Article

References (48)

1. Lee J and Zhou P. Pathogenic Role of the CRL4 Ubiquitin Ligase in Human Disease. Front Oncol. 2012; 2:21.
2. Sugasawa K. The CUL4 enigma: culling DNA repair factors. Mol Cell. 2009; 34(4):403-404.
3. Liu L, Lee S, Zhang J, Peters SB, Hannah J, Zhang Y, Yin Y, Koff A, Ma L and Zhou P. CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol Cell. 2009; 34(4):451-460.
4. Nishitani H, Shiomi Y, Iida H, Michishita M, Takami T and Tsurimoto T. CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem. 2008; 283(43):29045-29052.
5. Nag A, Bagchi S and Raychaudhuri P. Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res. 2004; 64(22):8152-8155.
6. Chen LC, Manjeshwar S, Lu Y, Moore D, Ljung BM, Kuo WL, Dairkee SH, Wernick M, Collins C and Smith HS. The human homologue for the Caenorhabditis elegans cul- 4 gene is amplified and overexpressed in primary breast cancers. Cancer Res. 1998; 58(16):3677-3683.
7. Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM and You L. Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med. 2009; 15(2):350-358.
8. Ren S, Xu C, Cui Z, Yu Y, Xu W, Wang F, Lu J, Wei M, Lu X, Gao X, Liang Y, Mao JH and Sun Y. Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med (Berl). 2012; 90(10):1121-1132.
9. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M and Inazawa J. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology. 2002; 35(6):1476-1484.
10. Schindl M, Gnant M, Schoppmann SF, Horvat R and Birner P. Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res. 2007; 27(2):949-952.
11. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, Labarge MA, You L, Kogan SC, Gray JW, Mao JH and Wei G. CUL4A Induces Epithelial-Mesenchymal Transition and Promotes Cancer Metastasis by Regulating ZEB1 Expression. Cancer Res. 2013; 74(2):520-531.
12. Melchor L, Saucedo-Cuevas LP, Munoz-Repeto I, Rodriguez-Pinilla SM, Honrado E, Campoverde A, Palacios J, Nathanson KL, Garcia MJ and Benitez J. Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res. 2009; 11(6):R86.
13. Melchor L, Honrado E, Garcia MJ, Alvarez S, Palacios J, Osorio A, Nathanson KL and Benitez J. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene. 2008; 27(22):3165-3175.
14. Foulkes WD, Smith IE and Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2012; 363(20):1938-1948.
15. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD and Pollack JR. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 2009; 4(7):e6146.
16. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10(6):515-527.
17. Tan BC, Chien CT, Hirose S and Lee SC. Functional cooperation between FACT and MCM helicase facilitates initiation of chromatin DNA replication. EMBO J. 2006; 25(17):3975-3985.
18. Yu W, Ding X, Chen F, Liu M, Shen S, Gu X and Yu L. The phosphorylation of SEPT2 on Ser218 by casein kinase 2 is important to hepatoma carcinoma cell proliferation. Mol Cell Biochem. 2009; 325(1-2):61-67.
19. Cherian MG, Jayasurya A and Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res. 2003; 533(1-2):201-209.
20. Di Cello F, Shin J, Harbom K and Brayton C. Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice. Biochem Biophys Res Commun. 2013; 434(1):70-74.
21. Xiong J, Du Q and Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010; 29(35):4980-4988.
22. Liu RZ, Graham K, Glubrecht DD, Germain DR, Mackey JR and Godbout R. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol. 2011; 178(3):997- 1008.
23. Wei N, Liu SS, Chan KK and Ngan HY. Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One. 2012; 7(1):e30311.
24. Abba MC, Fabris VT, Hu Y, Kittrell FS, Cai WW, Donehower LA, Sahin A, Medina D and Aldaz CM. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res. 2007; 67(9):4104-4112.
25. Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, Houdayer C, Sastre-Garau X, Vincent-Salomon A, Stoppa-Lyonnet D and Stern MH. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012; 72(21):5454-5462.
26. Carey LA. Breast cancer: HER2--a good addiction. Nat Rev Clin Oncol. 2012; 9(4):196-197.
27. Kuehl WM and Bergsagel PL. MYC addiction: a potential therapeutic target in MM. Blood. 2012; 120(12):2351-2352.
28. Garcia MJ, Saucedo-Cuevas LP, Munoz-Repeto I, Fernandez V, Robles MJ, Domingo S, Palacios J, Aracil M, Nieto A, Tercero JC and Benitez J. Analysis of DNA repairrelated genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response. Mol Cancer Ther. 2013; 12(4):530-541.
29. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009; 15(14):4649-4664.
30. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70.
31. Koman IE, Commane M, Paszkiewicz G, Hoonjan B, Pal S, Safina A, Toshkov I, Purmal AA, Wang D, Liu S, Morrison C, Gudkov AV and Gurova KV. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice. Cancer Prev Res (Phila). 2012; 5(8):1025-1035.
32. Shah SN, Cope L, Poh W, Belton A, Roy S, Talbot CC, Jr., Sukumar S, Huso DL and Resar LM. HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One. 2013; 8(5):e63419.
33. Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, Gudkov AV, et al. Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT. Sci Transl Med. 2012; 3(95):95ra74.
34. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB and Gonzalez-Angulo AM. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 2012; 14(5):R138.
35. Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S and Okada H. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother. 2012; 61(6):789-801.
36. Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, Pinheiro DG, Torres C, de Carvalho AF, Cury PM, Nunes FD, Nishimoto IN, Soares FA, da Silva AM, Kowalski LP, Brentani H, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia. 2009; 11(12):1329-1339.
37. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S and Lee PP. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009; 106(22):9010-9015.
38. Mushinski JF, Nguyen P, Stevens LM, Khanna C, Lee S, Chung EJ, Lee MJ, Kim YS, Linehan WM, Horisberger MA and Trepel JB. Inhibition of tumor cell motility by the interferon-inducible GTPase MxA. J Biol Chem. 2009; 284(22):15206-15214.
39. Reiser J, Hurst J, Voges M, Krauss P, Munch P, Iftner T and Stubenrauch F. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol. 2011; 85(21):11372-11380.
40. Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E and Fuchs SY. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 2003; 22(20):5480-5490.
41. Lee YR, Yuan WC, Ho HC, Chen CH, Shih HM and Chen RH. The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. EMBO J. 2010; 29(10):1748-1761.
42. Yuan C, Qi J, Zhao X and Gao C. Smurf1 protein negatively regulates interferon-gamma signaling through promoting STAT1 protein ubiquitination and degradation. J Biol Chem. 2012; 287(21):17006-17015.
43. Fulda S, Rajalingam K and Dikic I. Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med. 2012; 4(7):545-556.
44. Fulda S and Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012; 11(2):109-124.
45. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G and Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602.
46. Hellemans J, Mortier G, De Paepe A, Speleman F and Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007; 8(2):R19.
47. Wisniewski JR, Zougman A, Nagaraj N and Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009; 6(5):359-362.
48. Perkins DN, Pappin DJ, Creasy DM and Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999; 20(18):3551-3567.